The UK market remains one of the strongest in Europe. The total value of venture investments in biotech and other life science companies was lower in 2017 than in two previous years, but the number of financing rounds was impressive.
The UK market remains one of the strongest in Europe. The total value of venture investments in biotech and other life science companies was lower in 2017 than in two previous years, but the number of financing rounds was impressive.